This article explores a selection of banned PEDs in Crossfit on the principle that knowledge is power.
Performance enhancing drugs in sports are a controversial and universal reality, but one that must be fought against constantly. The information here is designed to give you an indication of how these drugs affect the human body. It is not difficult to imagine the pressures that could drive an athlete to take PEDs, but when people learn that many SARMS still only have alphanumerical code names because they have not yet been approved for human consumption and that medical trials had to be discontinued because the test mice were developing cancer, it may serve as a helpful deterrent.
On the final page, I have included much more information on CrossFit’s official drug policy and how they rigorously test athletes.
CROSSFIT BANS THE FOLLOWING CLASSES OF DRUGS AT ALL TIMES:
- Anabolic Agents
- Street Drugs
- Diuretics and Other Masking Agents
- Peptide Hormones and Analogues
- Anti-Estrogens and Metabolic Modulators
- Beta-2 Agonists (permitted with prescription and TUE, and through inhalation only)
TESTOLONE – RAD140
In 2017 Ricky Garard, a 23-year-old from Australia, lost the US$76,000 he’d won for his third-place overall finish and his first-place finishes in the Madison Triplet and Cyclocross events. He was also been banned from participating in any CrossFit-sanctioned event through the 2021 season, and his invitation to compete in the 2017 Reebok CrossFit Invitational was rescinded. He tested positive for testolone, and a beta-2 agonist known as endurobol.
Testolone, also known as RAD140, is a research compound being studied for the treatment of cancer and muscle wasting disorders. It is an orally bioavailable selective androgen receptor modulator (SARM) that has the ability to increase lean muscle mass and reinforce the effects of testosterone.
ENDUROBOL – GW 501516
Endurobol (GW 501516 or Cardarine) is a research chemical developed in the 1990s to prevent and cure tumour formation in the colon, prostate, and breasts. Studies done in the early 2000s have found that GW 501516 and other PPAR agonists have also been able to stop metabolic disorders such as obesity and diabetes through specific gene expressions. Endurobol was also found to have the ability to burn off excess fatty tissue, enhance recovery, and dramatically increase endurance.
The research was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs. WADA developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.